MEI Pharma, Inc. (MEIP)
Largest Insider Buys in Sector
MEIP Stock Price History Chart
MEIP Stock Performance
About MEI Pharma, Inc.
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and …
Insider Activity of MEI Pharma, Inc.
Over the last 12 months, insiders at MEI Pharma, Inc. have bought $0 and sold $0 worth of MEI Pharma, Inc. stock.
On average, over the past 5 years, insiders at MEI Pharma, Inc. have bought $2.13M and sold $100,625 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 48,060 shares for transaction amount of $329,331 was made by Anson Funds Management LP (10 percent owner) on 2023‑09‑22.
List of Insider Buy and Sell Transactions, MEI Pharma, Inc.
| 2023-09-22 | 10 percent owner | 48,060 0.6547% | $6.85 | $329,331 | -46.76% | |||
| 2023-09-22 | 10 percent owner | 32,040 0.4364% | $6.85 | $219,554 | -46.76% | |||
| 2023-09-21 | 10 percent owner | 33,600 0.4922% | $6.46 | $217,110 | -38.97% | |||
| 2023-09-21 | 10 percent owner | 22,400 0.3281% | $6.46 | $144,740 | -38.97% | |||
| 2023-09-20 | 10 percent owner | 120,000 1.7317% | $6.01 | $721,116 | -35.04% | |||
| 2023-09-20 | 10 percent owner | 80,000 1.1544% | $6.01 | $480,744 | -35.04% | |||
| 2023-02-28 | director | 81,500 0.0619% | $0.23 | $18,338 | +44.66% | |||
| 2021-02-23 | Sale | director | 25,000 0.0011% | $4.03 | $100,625 | -29.32% | ||
| 2019-12-19 | Chief Executive Officer | 18,750 0.0011% | $1.60 | $30,000 | +54.44% | |||
| 2019-12-19 | director | 62,500 0.0035% | $1.60 | $100,000 | +54.44% | |||
| 2019-12-19 | Chief Financial Officer | 12,500 0.0007% | $1.60 | $20,000 | +54.44% | |||
| 2019-12-19 | director | 10,000 0.0006% | $1.60 | $16,000 | +54.44% | |||
| 2019-09-06 | director | 15,000 0.001% | $1.74 | $26,075 | +32.37% | |||
| 2018-08-07 | Sale | Chief Operating Officer & GC | 9,500 0.0007% | $3.58 | $34,044 | -17.86% | ||
| 2017-11-27 | Sale | director | 11,000 0.0015% | $2.21 | $24,272 | +38.56% | ||
| 2017-11-27 | director | 11,000 0.0015% | $2.25 | $24,801 | +38.56% | |||
| 2015-11-09 | Sale | 10 percent owner | 314,704 0.0465% | $1.75 | $550,732 | -15.70% | ||
| 2015-11-09 | Sale | 10 percent owner | 18,284 0.0027% | $1.75 | $31,997 | -15.70% | ||
| 2015-11-06 | Sale | 10 percent owner | 15,120 0.0023% | $1.85 | $27,972 | -19.55% | ||
| 2015-11-06 | Sale | 10 percent owner | 880 0.0001% | $1.85 | $1,628 | -19.55% |
Insider Historical Profitability
| NOVOGEN LTD | 10 percent owner | 52408295 786.5736% | $2.36 | 1 | 0 | |
| Anson Funds Management LP | 10 percent owner | 864188 12.9702% | $2.36 | 3 | 0 | |
| Funicular Funds, LP | 10 percent owner | 460840 6.9165% | $2.36 | 3 | 0 | |
| GOLD DANIEL P PHD | Chief Executive Officer | 361632 5.4276% | $2.36 | 1 | 0 | +54.44% |
| Baltic Charles V. III | director | 105750 1.5872% | $2.36 | 10 | 1 | +30.85% |
Institutional Investor Ownership
| Anson Funds Management Lp | $4.37M | 16.41 | 1.09M | 0% | +$0 | 0.28 | |
| The Vanguard Group | $1.56M | 5.85 | 389,807 | 0% | +$0 | <0.0001 | |
| Acadian Asset Management | $845,000.00 | 3.18 | 211,733 | -6.06% | -$54,507.38 | <0.01 | |
| Renaissance Technologies | $572,000.00 | 2.15 | 143,092 | -5.17% | -$31,179.94 | <0.01 | |
| BlackRock | $330,464.00 | 1.24 | 82,616 | -0.84% | -$2,808.00 | <0.0001 |